503
Participants
Start Date
October 3, 2016
Primary Completion Date
June 26, 2019
Study Completion Date
June 26, 2019
Secukinumab
Anti IL-17a monoclonal antibody
Secukinumab and Placebo
Placebo matching AIN457
Novartis Investigative Site, Budapest
Novartis Investigative Site, Brussels
Novartis Investigative Site, Sofia
Novartis Investigative Site, Sofia
Novartis Investigative Site, Fribourg
Novartis Investigative Site, Sofia
Novartis Investigative Site, Leuven
Novartis Investigative Site, Eger
Novartis Investigative Site, Basel
Novartis Investigative Site, Rousse
Novartis Investigative Site, Veszprém
Novartis Investigative Site, Hévíz
Novartis Investigative Site, Torino
Novartis Investigative Site, Torino
Novartis Investigative Site, Tallinn
Novartis Investigative Site, Berlin
Novartis Investigative Site, Athens
Novartis Investigative Site, Córdoba
Novartis Investigative Site, A Coruña
Novartis Investigative Site, Santiago de Compostela
Novartis Investigative Site, Milan
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Bergamo
Novartis Investigative Site, Lugo
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, El Palmar
Novartis Investigative Site, Plzen-Bory
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Las Palmas de Gran Canaria
Novartis Investigative Site, Pontevedra
Novartis Investigative Site, Salamanca
Novartis Investigative Site, Verona
Novartis Investigative Site, Santander
Novartis Investigative Site, Magdeburg
Novartis Investigative Site, Bologna
Novartis Investigative Site, Seville
Novartis Investigative Site, Nantes
Novartis Investigative Site, Kfar Saba
Novartis Investigative Site, Bochum
Novartis Investigative Site, Kuovola
Novartis Investigative Site, Tartu
Novartis Investigative Site, Ramat Gan
Novartis Investigative Site, Vandœuvre-lès-Nancy
Novartis Investigative Site, Brno
Novartis Investigative Site, Strasbourg
Novartis Investigative Site, Lyon
Novartis Investigative Site, Kuopio
Novartis Investigative Site, Paris
Novartis Investigative Site, Moscow
Novartis Investigative Site, Moscow
Novartis Investigative Site, Moscow
Novartis Investigative Site, Yaroslavl
Novartis Investigative Site, Kursk
Novartis Investigative Site, Haifa
Novartis Investigative Site, Cluj-Napoca
Novartis Investigative Site, Saratov
Novartis Investigative Site, Kazan'
Novartis Investigative Site, Izhevsk
Novartis Investigative Site, Orenburg
Novartis Investigative Site, Khanty-Mansiysk
Novartis Investigative Site, Novosibirsk
Novartis Investigative Site, Tel Aviv
Novartis Investigative Site, Brussels
Novartis Investigative Site, Bruntál
Novartis Investigative Site, Uherské Hradiště
Novartis Investigative Site, Cottbus
Novartis Investigative Site, Athens
Novartis Investigative Site, Miskolc
Novartis Investigative Site, Dublin
Novartis Investigative Site, Bialystok
Novartis Investigative Site, Bydgoszcz
Novartis Investigative Site, Krakow
Novartis Investigative Site, Piotrkow Trybunalski
Novartis Investigative Site, Poznan
Novartis Investigative Site, Poznan
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Bucharest
Novartis Investigative Site, Bucharest
Novartis Investigative Site, Elche
Novartis Investigative Site, Terrassa
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Vitoria-Gasteiz
Novartis Investigative Site, Sankt Gallen
Novartis Investigative Site, Zurich
Novartis Investigative Site, Devon
Novartis Investigative Site, Basingstoke
Novartis Investigative Site, Maidstone
Novartis Investigative Site, Leytonstone
Novartis Investigative Site, Bradford
Novartis Investigative Site, Leeds
Novartis Investigative Site, Hull
Novartis Investigative Site, Wigan
Novartis Investigative Site, Wolverhampton
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY